title: Effectiveness of alendronate treatment in postmenopausal women with osteoporosis: relationship with BsmI vitamin D receptor genotypes.
abstract: OBJECTIVE
  To assess whether there is a relationship between the effectiveness of alendronate treatment in postmenopausal women with osteoporosis and BsmI vitamin D receptor (VDR) genotypes.
  
  
  METHODS
  Prospective baseline-controlled clinical trial.
  
  
  METHODS
  Sixty-eight Italian osteoporotic women were enrolled and treated with alendronate at a dose of 10 mg/day for 12 months.
  
  
  METHODS
  At entry and after treatment, lumbar bone mineral density (BMD) and serum osteocalcin (OC) and urinary deoxypyridinoline/creatinine ratio (DPD-Cr) levels were evaluated. DNA was extracted from blood and analysed for the BsmI polymorphism of the VDR gene.
  
  
  RESULTS
  The mean percentage (% +/- SD) change from baseline in lumbar BMD was significantly higher (P < 0.01) in bb than in BB BsmI VDR genotypes (7.92 +/- 4.31 vs. 3.40 +/- 1.81). No significant difference in lumbar BMD was observed in Bb VDR patients (6.01 +/- 3.89) in comparison with other groups. The mean percentage of change in serum OC and urinary DPD-Cr levels was significantly (P < 0.01) lower in individuals with bb than in those with BB BsmI VDR genotypes (-14.34 +/- 2.87 vs.-10.39 +/- 1.43 and -9.61 +/- 5.56 vs.-4.61 +/- 2.31). No significant difference in serum OC and urinary DPD-Cr levels was observed in Bb VDR patients (-12.31 +/- 2.11 and -6.52 +/- 2.65) in comparison with other groups.
  
  
  CONCLUSIONS
  The different BsmI vitamin D receptor genotypes modify the pharmacological response to alendronate treatment in postmenopausal women with osteoporosis.
authors.affiliation: University of Catanzaro, Catanzaro, Italy. stefanopalomba@tin.it
authors.forename: Stefano
authors.initials: S
authors.lastname: Palomba
authors.forename: Fabio Giuliano
authors.initials: FG
authors.lastname: Numis
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Mossetti
authors.forename: Domenico
authors.initials: D
authors.lastname: Rendina
authors.forename: Pietro
authors.initials: P
authors.lastname: Vuotto
authors.forename: Tiziana
authors.initials: T
authors.lastname: Russo
authors.forename: Fulvio
authors.initials: F
authors.lastname: Zullo
authors.forename: Carmine
authors.initials: C
authors.lastname: Nappi
authors.forename: Vincenzo
authors.initials: V
authors.lastname: Nunziata
mesh_terms: D000368:Aged; D019386:Alendronate / Q000627:therapeutic use*; D000596:Amino Acids / Q000652:urine; D015415:Biomarkers / Q000097:blood / Q000652:urine; D015519:Bone Density; D003404:Creatinine / Q000652:urine; D005260:Female; D006801:Humans; D008159:Lumbar Vertebrae; D008875:Middle Aged; D015675:Osteocalcin / Q000097:blood; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy* / Q000235:genetics / Q000503:physiopathology; D011110:Polymorphism, Genetic; D011446:Prospective Studies; D018167:Receptors, Calcitriol / Q000235:genetics*; D016896:Treatment Outcome
chemical_list: D000596:Amino Acids; D015415:Biomarkers; D018167:Receptors, Calcitriol; D015675:Osteocalcin; C036020:deoxypyridinoline; D003404:Creatinine; D019386:Alendronate